Detailed explanation of the usage and precautions of Incepta version of ibrutinib/ibrutinib

Ibrutinib (generic name: Ibrutinib, also known as ibrutinib) is the world's first marketed Bruton's tyrosine kinase (BTK) inhibitor, which was jointly developed by Johnson & Johnson and Pharmacyclics. The drug can inhibit the activity of BTK, thereby inhibiting the proliferation and survival of B cells, and is effective against a variety of BCellular lymphomas such as chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) have significant curative effects. However, original drugs are relatively expensive and difficult for patients to afford. However, Bangladesh Istar has launched a more economical generic version, which is favored by more patients. Patients are still unclear about its usage and precautions, and this article will introduce it in detail.

1. How to use

Ibrutinib/Ibrutinib is usually provided in capsule form, with each capsule having a strength of 140mg. The specific dosage needs to be determined by the doctor based on the patient's condition. In general, for patients withCLL/SLL and WM the recommended dose is usually 3 capsules once daily (i.e. 420mg) until disease progression or unacceptable toxicity occurs. For cGVHD, the recommended dose for patients 12 years and older is 420mg once daily, and for 1 years to 1 The recommended dose for patients under 2 years of age is 240 mg/m once daily (The maximum dose is 420 mg/m once daily). Patients should take the medicine at a fixed time every day and swallow the capsule whole with water. Do not open, break or chew the capsule. Be careful not to take it with foods or drinks containing grapefruit, Seville orange, etc. that may affect drug metabolism.

2. Precautions

1. Side effect monitoring: During the use of ibrutinib, patients should pay close attention to their own conditions and pay attention to possible side effects, such as bleeding, infection, heart problems, etc. Go to the hospital regularly for blood routine and infection indicator monitoring to detect and deal with side effects in a timely manner.

2. Prevention of infection: Ibrutinib may suppress immune system function and increase the risk of infection. Therefore, patients should avoid contact with sources of infection, such as cold or flu patients, maintain personal hygiene and wash hands frequently during treatment.

3. Drug Interactions: Inform your doctor of all medications you are taking, including prescription drugs, over-the-counter drugs, and supplements, to avoid drug-drug interactions. In particular, strong or moderate inhibitors of CYP3A may affect the metabolism of ibrutinib.

4. Medication for special populations: Patients with mild or moderate liver damage may need to adjust the dose, while patients with severe liver damage should avoid using ibrutinib. Women of childbearing age should take effective contraceptive measures during treatment and for a period of time after treatment.

5. Regular follow-up visits: Follow the doctor’s recommendations for regular follow-up visits to evaluate the treatment effects and side effects. Report any symptoms or concerns promptly so your doctor can adjust your treatment plan.

In short, Inceptaversion of ibrutinib/ibrutinib provides patients with an affordable treatment option. Patients should strictly follow medical instructions during use and pay attention to medication methods and precautions to ensure the safety and effectiveness of treatment. If you have any questions or discomfort, please consult your doctor promptly.